RESEARCH PAPER
Keratinocyte growth factor decreases incidence of severe oral mucositis in children undergoing autologous hematopoietic stem cell transplantation
 
More details
Hide details
1
Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Antoni Jurasz University Hospital, Bydgoszcz, Poland
CORRESPONDING AUTHOR
Krzysztof Czyżewski   

Department of Pediatric Hematology and Oncology, Antoni Jurasz University Hospital, M. Skłodowskiej-Curie 9, 85-094 Bydgoszcz, Poland. Tel.: +48 525 85 48 60; fax: +48 52 585 4867.
Submission date: 2014-08-13
Acceptance date: 2015-04-09
Online publication date: 2015-05-11
Publication date: 2020-03-24
 
Pol. Ann. Med. 2015;22(1):18–22
 
KEYWORDS
ABSTRACT
Introduction:
Keratinocyte growth factor (palifermin) is used for the prevention of mucositis in adults following autologous and allogeneic hematopoietic stem cell transplantation (HSCT). It is known that palifermin decreases length of initial hospital stay, mean number of days of total parenteral nutrition and the use of opioids for pain control in oral mucositis in adults. There are limited data evaluating palifermin use in children following autologous HSCT.

Aim:
The aim of this study was to analyze the efficacy and safety of palifermin in children and adolescents following autologous HSCT.

Material and methods:
The study included 81 consecutive patients. Results of efficacy and safety of palifermin in 18 patients were compared to data of 63 patients not treated with palifermin.

Results and discussion:
Palifermin decreased the incidence of severe oral mucositis (grade 3–4 WHO) by 19% (44% vs. 63%), however it did not contribute to the duration of oral mucositis and total parenteral nutrition use. There were no differences in opioid use, incidence of fever of unknown origin, severe infection, engraftment and gastrointestinal hemorrhage between groups. Five-year overall survival was better in patients treated with palifermin. Only in one patient generalized, itching rash was observed after palifermin administration.

Conclusions:
Palifermin decreases incidence of severe oral mucositis and improves overall survival in children undergoing autologous HSCT.

CONFLICT OF INTEREST
There are no financial or other relationship considerations that could lead to any conflict of interest.
FUNDING
None.
 
REFERENCES (17)
1.
Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351(25):2590–2598.
 
2.
Miller MM, Donald DV, Hagemann TM. Prevention and treatment of oral mucositis in children with cancer. J Pediatr Pharmacol Ther. 2012;17(4):340–350.
 
3.
Nasilowska-Adamska B, Szydlo R, Rzepecki P, et al. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT. Ann Transplant. 2011;16(4):47–54.
 
4.
Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol. 2004;22(7):1268–1275.
 
5.
Goldberg JD, Zheng J, Castro-Malaspina H, et al. Palifermin is efficacious in recipients of tbi-based but not chemotherapy- based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant. 2013;48(1):99–104.
 
6.
Otmani N, Alami R, Hessissen L, Mokhtari A, Soulaymani A, Khattab M. Determinants of severe oral mucositis in paediatric cancer patients: a prospective study. Int J Paediatr Dent. 2011;21(3):210–216.
 
7.
Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31(8):705–712.
 
8.
Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201–2205.
 
9.
Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versushost disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 2006;108(9):3216–3222.
 
10.
Srinivasan A, Kasow KA, Cross S, et al. Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(8):1309–1314.
 
11.
Vitale KM, Violago L, Cofnas P, et al. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases. Pediatr Transplant. 2014;18(2):211–216.
 
12.
WHO. Handbook for Reporting Results of Cancer Treatment. vol. 48. Geneva: World Health Organization; 1979: 15–21.
 
13.
Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant. 2007;40(10):983–988.
 
14.
Czyzewski K, Styczynski J, Debski R, Krenska A, Wysocki M. [Palifermin use in children and adolescents undergoing allogeneic hematopoietic stem cell transplantation]. Postepy Nauk Med. 2013;26(9):615–621 [in Polish].
 
15.
Lauritano D, Petruzzi M, Di Stasio D, Lucchese A. Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study. Int J Oral Sci. 2014;6(1):27–30.
 
16.
Blijlevens N, de Chateau M, Krivan G, et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant. 2013;48(7):966–971.
 
17.
Vadhan-Raj S, Trent J, Patel S, et al. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010;153(6):358–367.